[
  {
    "ts": null,
    "headline": "Forecasting The Future: 6 Analyst Projections For Quest Diagnostics",
    "summary": "",
    "url": "https://finnhub.io/api/news?id=729913936dd082504f0a2b78a07dff29ba88629cdfa87626ad459d8767f81fca",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770832850,
      "headline": "Forecasting The Future: 6 Analyst Projections For Quest Diagnostics",
      "id": 139058045,
      "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/analyst_ratings_3.jpg?width=2048&height=1536",
      "related": "DGX",
      "source": "Benzinga",
      "summary": " ",
      "url": "https://finnhub.io/api/news?id=729913936dd082504f0a2b78a07dff29ba88629cdfa87626ad459d8767f81fca"
    }
  },
  {
    "ts": null,
    "headline": "Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue?",
    "summary": "Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.",
    "url": "https://finnhub.io/api/news?id=587d819d48e6bec72d3f715125779e55b451250cd4b70a84467afdf16550b472",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770819303,
      "headline": "Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue?",
      "id": 139046727,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.",
      "url": "https://finnhub.io/api/news?id=587d819d48e6bec72d3f715125779e55b451250cd4b70a84467afdf16550b472"
    }
  },
  {
    "ts": null,
    "headline": "Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $220",
    "summary": "Truist Securities  analyst David Macdonald   maintains Quest Diagnostics (NYSE:DGX) with a Hold and raises the price target from $205 to $220.",
    "url": "https://finnhub.io/api/news?id=451abf8ce0c938a9e94ebef44c3bc09554eebfac046c39ac9242fe2e2e7ff91e",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770813497,
      "headline": "Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $220",
      "id": 139058046,
      "image": "",
      "related": "DGX",
      "source": "Benzinga",
      "summary": "Truist Securities  analyst David Macdonald   maintains Quest Diagnostics (NYSE:DGX) with a Hold and raises the price target from $205 to $220.",
      "url": "https://finnhub.io/api/news?id=451abf8ce0c938a9e94ebef44c3bc09554eebfac046c39ac9242fe2e2e7ff91e"
    }
  },
  {
    "ts": null,
    "headline": "UBS Maintains Neutral on Quest Diagnostics, Raises Price Target to $210",
    "summary": "UBS  analyst Kevin Caliendo   maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $190 to $210.",
    "url": "https://finnhub.io/api/news?id=b906b920017ed33f0678e5d0f46d1047bea17cfcf2cf0972c0d4d15d17e7f892",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770812430,
      "headline": "UBS Maintains Neutral on Quest Diagnostics, Raises Price Target to $210",
      "id": 139058047,
      "image": "",
      "related": "DGX",
      "source": "Benzinga",
      "summary": "UBS  analyst Kevin Caliendo   maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $190 to $210.",
      "url": "https://finnhub.io/api/news?id=b906b920017ed33f0678e5d0f46d1047bea17cfcf2cf0972c0d4d15d17e7f892"
    }
  },
  {
    "ts": null,
    "headline": "Evercore ISI Group Maintains In-Line on Quest Diagnostics, Raises Price Target to $220",
    "summary": "Evercore ISI Group  analyst Elizabeth Anderson   maintains Quest Diagnostics (NYSE:DGX) with a In-Line and raises the price target from $190 to $220.",
    "url": "https://finnhub.io/api/news?id=40765b2ab27d7fe296bfb9fd362cd0eab98bed53a715cdabaa533f4e3c210402",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770805480,
      "headline": "Evercore ISI Group Maintains In-Line on Quest Diagnostics, Raises Price Target to $220",
      "id": 139044361,
      "image": "",
      "related": "DGX",
      "source": "Benzinga",
      "summary": "Evercore ISI Group  analyst Elizabeth Anderson   maintains Quest Diagnostics (NYSE:DGX) with a In-Line and raises the price target from $190 to $220.",
      "url": "https://finnhub.io/api/news?id=40765b2ab27d7fe296bfb9fd362cd0eab98bed53a715cdabaa533f4e3c210402"
    }
  },
  {
    "ts": null,
    "headline": "Barclays Maintains Overweight on Quest Diagnostics, Raises Price Target to $225",
    "summary": "Barclays  analyst Stephanie Davis   maintains Quest Diagnostics (NYSE:DGX) with a Overweight and raises the price target from $210 to $225.",
    "url": "https://finnhub.io/api/news?id=7b158a12cb87898fec7d601823ad0a216eee18b60da9be72922d85699065d7da",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770805186,
      "headline": "Barclays Maintains Overweight on Quest Diagnostics, Raises Price Target to $225",
      "id": 139044362,
      "image": "",
      "related": "DGX",
      "source": "Benzinga",
      "summary": "Barclays  analyst Stephanie Davis   maintains Quest Diagnostics (NYSE:DGX) with a Overweight and raises the price target from $210 to $225.",
      "url": "https://finnhub.io/api/news?id=7b158a12cb87898fec7d601823ad0a216eee18b60da9be72922d85699065d7da"
    }
  },
  {
    "ts": null,
    "headline": "Walmart To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Wednesday",
    "summary": "",
    "url": "https://finnhub.io/api/news?id=db2cca672722ec3d02457f8415f887657f39cdbb99478148dcf691f35405382a",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770798668,
      "headline": "Walmart To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Wednesday",
      "id": 139041788,
      "image": "https://cdn.benzinga.com/files/images/story/2026/02/11/Closeup-Of-The-Walmart-Logo-Seen-At-One-.jpeg?width=2048&height=1536",
      "related": "DGX",
      "source": "Benzinga",
      "summary": " ",
      "url": "https://finnhub.io/api/news?id=db2cca672722ec3d02457f8415f887657f39cdbb99478148dcf691f35405382a"
    }
  },
  {
    "ts": null,
    "headline": "Jefferies Maintains Buy on Quest Diagnostics, Raises Price Target to $220",
    "summary": "Jefferies  analyst Tycho Peterson   maintains Quest Diagnostics (NYSE:DGX) with a Buy and raises the price target from $215 to $220.",
    "url": "https://finnhub.io/api/news?id=d4753d6a1c0a0bbbf892548c3c1514fd52eb412008b37ba211089f73415621ce",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770796463,
      "headline": "Jefferies Maintains Buy on Quest Diagnostics, Raises Price Target to $220",
      "id": 139044364,
      "image": "",
      "related": "DGX",
      "source": "Benzinga",
      "summary": "Jefferies  analyst Tycho Peterson   maintains Quest Diagnostics (NYSE:DGX) with a Buy and raises the price target from $215 to $220.",
      "url": "https://finnhub.io/api/news?id=d4753d6a1c0a0bbbf892548c3c1514fd52eb412008b37ba211089f73415621ce"
    }
  },
  {
    "ts": null,
    "headline": "DGX Q4 Deep Dive: Consumer Testing and Advanced Diagnostics Fuel Growth Amid Margin Headwinds",
    "summary": "Healthcare diagnostics company Quest Diagnostics (NYSE:DGX) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 7.1% year on year to $2.81 billion. The company’s full-year revenue guidance of $11.76 billion at the midpoint came in 3.3% above analysts’ estimates. Its non-GAAP profit of $2.42 per share was 2.6% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=587a144842693751d8353895a2c1f6c16e1450601eb9910431f13bbbb1dbed70",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770787943,
      "headline": "DGX Q4 Deep Dive: Consumer Testing and Advanced Diagnostics Fuel Growth Amid Margin Headwinds",
      "id": 139042607,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Healthcare diagnostics company Quest Diagnostics (NYSE:DGX) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 7.1% year on year to $2.81 billion. The company’s full-year revenue guidance of $11.76 billion at the midpoint came in 3.3% above analysts’ estimates. Its non-GAAP profit of $2.42 per share was 2.6% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=587a144842693751d8353895a2c1f6c16e1450601eb9910431f13bbbb1dbed70"
    }
  },
  {
    "ts": null,
    "headline": "Quest Diagnostics Q4 Earnings Call Highlights",
    "summary": "Quest Diagnostics (NYSE:DGX) executives highlighted what they described as strong execution in 2025 and outlined expectations for continued organic growth in 2026, while also discussing a one-year delay in PAMA rate cuts, the ramp of major partnerships, and ongoing investment in operational moderniz",
    "url": "https://finnhub.io/api/news?id=cc78f8e6124e6018ed634a96f7cecd64e1f51ca777f6c502ccd1d117f2e62f38",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770779237,
      "headline": "Quest Diagnostics Q4 Earnings Call Highlights",
      "id": 139038932,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DGX",
      "source": "Yahoo",
      "summary": "Quest Diagnostics (NYSE:DGX) executives highlighted what they described as strong execution in 2025 and outlined expectations for continued organic growth in 2026, while also discussing a one-year delay in PAMA rate cuts, the ramp of major partnerships, and ongoing investment in operational moderniz",
      "url": "https://finnhub.io/api/news?id=cc78f8e6124e6018ed634a96f7cecd64e1f51ca777f6c502ccd1d117f2e62f38"
    }
  }
]